fashion -WSS

fashion

author：fashion 2025-09-29 21:29:09 - browse：284

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： David Sabatini, ex

leisure time

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Poor hospice wound care hurts patients and families

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Childhood cancer progress stalls for Black, Hispanic kids: Report

Why medical students are struggling with mental health

FDA's Woodcock to retire early next year

hotspot

fashion

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

In Memoriam: Notable people who died in 2023

'Revelatory' study finds a smoking impact that remains after quitting

Hepatitis C has a cure — but many Americans still lack access to it

Robert F. Kennedy is pitching centrism on health, even on abortion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

PBM reforms clear House panel

Guidelines to prevent youth baseball injuries need more muscle

Weight loss drug costs may need more research, senator suggests

hotspot

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Wegovy, Zepbound and weight loss drugs that preserve muscle

'Revelatory' study finds a smoking impact that remains after quitting

CRISPR pioneers react to Casgevy, first gene

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

BioAge raises $170M for combination therapy with Zepbound

knowledge

focus

leisure time

focus